IV (Adults ): 0.5 ng/kg/min initially as continuous infusion (based on actual body weight); then titrate by 0.5 ng/kg/min every 30 min based on tolerability up to 2 ng/kg/min. Continue infusion for 6 hr each day for up to a maximum of 8 consecutive days. Repeat dosage titration steps on Days 2 and 3; from Day 4 and thereafter, start at highest tolerated infusion rate from previous day and adjust, if needed, based on tolerability.
Renal Impairment
IV (Adults ): CCr <30 mL/min: 0.25–0.5 ng/kg/min initially as continuous infusion (based on actual body weight); then titrate by 0.5 ng/kg/min every 30 min based on tolerability up to 2 ng/kg/min. Continue infusion for 6 hr each day for up to a maximum of 8 consecutive days. Repeat dosage titration steps on Days 2 and 3; from Day 4 and thereafter, start at highest tolerated infusion rate from previous day and adjust, if needed, based on tolerability. Hemodialysis: Start administration of infusion at the end of hemodialysis session or start hemodialysis ≥1 hr after end of infusion.
Hepatic Impairment
IV (Adults ): Moderate or severe hepatic impairment: 0.25 ng/kg/min initially as continuous infusion (based on actual body weight); then titrate by 0.5 ng/kg/min every 30 min based on tolerability up to 2 ng/kg/min. Continue infusion for 6 hr each day for up to a maximum of 8 consecutive days. Repeat dosage titration steps on Days 2 and 3; from Day 4 and thereafter, start at highest tolerated infusion rate from previous day and adjust, if needed, based on tolerability.
US Brand Names⬆⬇
Aurlumyn
Action⬆⬇
Dilates pulmonary and arterial vasculature and inhibits platelet aggregation.
Therapeutic effects:
Reduction in risk of digit amputation due to frostbite.
Classifications⬆⬇
Therapeutic Classification: vasodilators
Pharmacologic Classification: prostacyclins
Pharmacokinetics⬆⬇
Absorption: IV administration results in complete bioavailability.
Distribution: Well distributed to tissues.
Metabolism/Excretion: Primarily metabolized and excreted into urine.
Half-Life: 20–30 min.
Time/Action Profile⬆⬇
ROUTE
ONSET
PEAK
DURATION
IV
unknown
unknown
unknown
Patient/Family Teaching⬆⬇
May cause dizziness and fainting due to hypotension. Caution patient to change positions slowly to minimize orthostatic hypotension.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during therapy.
